|
HME
MCID: HRD001
|
Hereditary Multiple Exostoses malady |
|
Sources: 6Disease Ontology, 30NIH Rare Diseases, 17Genetics Home Reference, 15GeneReviews, 22MalaCards See all sources Export this MalaCard |
NIH Rare Diseases: Hereditary multiple osteochondromas (HMO) (formerly called hereditary multiple exostoses) is a genetic condition in which people develop multiple benign (noncancerous) bone tumors that are covered by cartilage (called osteochondromas). The number and location of osteochondromas varies greatly among affected individuals. These tumors are not present at birth, but almost all affected people develop multiple osteochondromas by the time they are 12 years old. Once the bones stop growing, the development of new osteochondromas also usually stops. Osteochondromas can cause abnormal growth of the arms, hands, and legs, which can lead to uneven limb lengths (limb length discrepancy) and short stature. These tumors may cause pain, limit joint movement, and exert pressure on nerves, blood vessels, and surrounding tissues. Osteochondromas are typically benign; however, researchers estimate that people with HMO have about a 1% lifetime risk of these tumors becoming a cancerous osteochondrosarcoma. HMO is caused by mutations in the EXT1 and EXT2 genes and is inherited in an autosomal dominant pattern.30
MalaCards: Hereditary Multiple Exostoses, also known as hereditary multiple osteochondromas, is related to exostoses and enchondromatosis. An important gene associated with Hereditary Multiple Exostoses is EXTL3 (exostoses (multiple)-like 3), and among its related pathways are Signal transduction_AKT signaling and Signal transduction AKT signaling. The compound heparan sulfate have been mentioned in the context of this disorder. Affiliated tissues include colon and myeloid. Disease Ontology: An exostosis that has material basis in a mutation on the genes ext1, ext2 and ext3 which results in multiple bony spurs throughout a child's growth.6 Genetics Home Reference: Hereditary multiple exostoses is a condition in which people develop multiple benign (noncancerous) bone tumors called exostoses. The number of exostoses and the bones on which they are located vary greatly among affected individuals. The exostoses are not present at birth, but approximately 96 percent of affected people develop multiple exostoses by the time they are 12 years old. Once people with hereditary multiple exostoses reach adult height and their bones stop growing, the development of new exostoses also usually stops.17 Wikipedia: Hereditary multiple exostoses (HME or MHE), also known as Diaphyseal aclasis, is a rare medical...44 more... GeneReviews summary for ext |
|
Sources: 17Genetics Home Reference, 43UMLS, 6Disease Ontology, 44Wikipedia, 15GeneReviews, 30NIH Rare Diseases, 16GeneTests, 32Novoseek , 24MeSH, 33OMIM, 40SNOMED-CT, 27NCIt See all sources |
Aliases & Descriptions:
|
|
|
|
Sources: 4CenterWatch, 29NIH Clinical Center, 5ClinicalTrials, 43UMLS, 28NDF-RT See all sources |
Approved drugs:Search CenterWatch for hereditary multiple exostoses Drug clinical trials:Search ClinicalTrials for hereditary multiple exostoses Search NIH Clinical Center for hereditary multiple exostoses Search CenterWatch for hereditary multiple exostoses |
|
|
|
Sources: 22MalaCards See all sources |
MalaCards organs/tissues related to hereditary multiple exostoses:22Colon, Myeloid
|
|
|
|
Sources: 35PubMed See all sources |
Articles related to hereditary multiple exostoses:(show all 45)
|
|
Sources: 1BioGPS See all sources |
![]() |
|
Sources: 41Thomson Reuters, 10EMD Millipore, 20KEGG See all sources |
Pathways related to hereditary multiple exostoses according to GeneDecks:
|
|
Sources: 32Novoseek , 18HMDB See all sources |
|
Sources: 12Gene Ontology See all sources |
Cellular components related to hereditary multiple exostoses according to GeneDecks:
Biological processes related to hereditary multiple exostoses according to GeneDecks:
Molecular functions related to hereditary multiple exostoses according to GeneDecks:(show all 8)
|
